{
    "clinical_study": {
        "@rank": "62270", 
        "arm_group": [
            {
                "arm_group_label": "PLACEBO", 
                "arm_group_type": "Placebo Comparator", 
                "description": "500 mg PLACEBO PO 2 times a day for 1 week (Week 1)\n1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
            }, 
            {
                "arm_group_label": "RANOLAZINE", 
                "arm_group_type": "Active Comparator", 
                "description": "500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)\n1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine if patients suffering from diabetic peripheral\n      neuropathic pain treated with ranolazine will have a greater reduction in pain compared to\n      placebo.\n\n      Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical\n      animal model of neuropathic pain, the investigators hypothesize that subjects randomized to\n      ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo."
        }, 
        "brief_title": "Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Peripheral Neuropathic Pain", 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Diabetic Neuropathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. A minimum of 18 years of age;\n\n          2. Provided signed Informed Consent Form and Health Insurance Portability and\n             Accountability Act (HIPAA) authorization for this study approved by the Institutional\n             Review Board;\n\n          3. Patients must have diabetic peripheral neuropathic pain rated at an average level of\n             six (6) or above as documented in daily diary prior to baseline visit and noted at\n             Baseline Visit;\n\n          4. Diabetic on a stable insulin regimen or oral medication regimen as determined by the\n             investigator  [It is recommended Hba1c < 9.5%, making a note that lab normal values\n             may vary among sites.];\n\n          5. Clinical Exam Results:\n\n               1. 5.07 Semmes-Weinstein Monofilament Test Subject does not sense monofilament or\n                  evokes an abnormal response in a minimum of two (2) out of five (5) test\n                  locations on the plantar surface of the foot.\n\n               2. Pin Prick Test Subject experiences allodynia, hyperalgesia, or sensory loss in\n                  two (2) out of five (5) test locations in the plantar surface - four (4) and\n                  dorsum - one (1) of the foot.\n\n          6. Willing and able to comply with the requirements of the protocol and follow\n             directions from the clinic and research staff;\n\n          7. For female patients only:\n\n               -  Be post-menopausal (no menses for at least 2 years) or sterilized,\n\n               -  If subject of childbearing potential, not breastfeeding, has a negative\n                  pregnancy test at Baseline (pre-randomization, Day 0), has no intention of\n                  becoming pregnant during the course of the study, and is using one or more of\n                  the following contraceptive measures:\n\n                    1. Stable regimen of hormonal contraception\n\n                    2. Intra-uterine device\n\n                    3. Condoms with spermicide\n\n                    4. Diaphragm with spermicide\n\n        Exclusion Criteria:\n\n          1. History of allergy or intolerance to ranolazine;\n\n          2. Any condition or concomitant medication that would preclude the safe use of\n             ranolazine as outlined in the prescribing information sheet;\n\n          3. In the judgment of the investigator, any clinically-significant ongoing medical\n             condition that might jeopardize the patient's safety or interfere with the\n             absorption, distribution, metabolism or excretion of the study drug;\n\n          4. In the judgment of the investigator, clinically-significant  abnormal physical\n             findings during screening (excluding the patient's peripheral neuropathy condition);\n\n          5. Use participation in another experimental or investigational drug or device trial;\n\n          6. Pregnant or breast feeding;\n\n          7. Cirrhosis of the liver;\n\n          8. Psychological or addictive disorders (not limited to, but including for example, drug\n             and/or alcohol dependency) that may preclude patient consent or compliance, or that\n             may confound study interpretation;\n\n          9. Taking a moderate or strong CYP3A inhibitor (e.g. diltiazem, verapamil, ketoconazole,\n             itraconazole, clarithromycin, erythromycin, nefazodone, nelfinavir, ritonavir,\n             indinavir, and saquinavir);\n\n         10. Taking inducers of Cytochrome P450, family 3, subfamily A (CYP3A) (e.g. rifampin,\n             rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's\n             wort);\n\n         11. Renal impairment as defined by a calculated serum creatinine clearance of < 30ml/min;\n\n         12. Lower back disorders where symptoms present similarly to DPNP;\n\n         13. Family history of long QT syndrome;\n\n         14. Congenital long QT syndrome;\n\n         15. Subjects taking tricyclic antidepressants;\n\n         16. Subjects taking anti-psychotic drugs;\n\n         17. Patient is taking > 1000mg metformin BID;\n\n         18. Any subjects currently taking pregabalin;\n\n         19. Any subjects currently taking gabapentin;\n\n         20. Any subject currently taking Metanx\u00ae;\n\n         21. Any subjects currently taking continuous long-term narcotics;\n\n         22. Grapefruit and grapefruit containing products;\n\n         23. Use of P-gp inhibitors - cyclosporine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156336", 
            "org_study_id": "HIPG-CLIN-2014-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "RANOLAZINE", 
                "description": "Oral administration, BID; for a maximum of 51 days.", 
                "intervention_name": "Ranolazine", 
                "intervention_type": "Drug", 
                "other_name": "Ranexa"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "description": "Oral administration, BID; for a maximum of 51 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sugar Pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetic Peripheral Neuropathic Pain", 
            "Ranexa", 
            "Ranolazine", 
            "Neurology"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "MAustin@cardassoc.com", 
                    "last_name": "Mary Austin, RN", 
                    "phone": "251-999-1936"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairhope", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36532"
                    }, 
                    "name": "Cardiology Associates"
                }, 
                "investigator": {
                    "last_name": "Frank T Bunch, MD FACC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Deanna.Benoit@cardio.com", 
                    "last_name": "Deanna K Benoit, LPN", 
                    "phone": "985-873-5613"
                }, 
                "facility": {
                    "address": {
                        "city": "Houma", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70361"
                    }, 
                    "name": "Cardiovascular Institute of the South"
                }, 
                "investigator": {
                    "last_name": "Craig M Walker, MD FACC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Shontel.Cleveland@cardio.com", 
                    "last_name": "Shontel Cleveland, LPN", 
                    "phone": "337-289-8429"
                }, 
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70503"
                    }, 
                    "name": "Cardiovascular Institute of the South"
                }, 
                "investigator": {
                    "last_name": "Nick Cavros, MD FACC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)", 
        "overall_contact": {
            "email": "CSchultz@ecr-inc.com", 
            "last_name": "Chris A Schultz, BS", 
            "phone": "971-506-7552"
        }, 
        "overall_official": {
            "affiliation": "Cardiovascular Institute of the South", 
            "last_name": "Craig M Walker, MD FACC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.", 
            "safety_issue": "No", 
            "time_frame": "6 weeks (42 Days)"
        }, 
        "reference": {
            "PMID": "19773645", 
            "citation": "Gould HJ 3rd, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol. 2009 Dec;20(8):755-8. doi: 10.1097/FBP.0b013e3283323c90. PubMed"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Quality of Life Assessment as measured by SF-36 v2", 
                "safety_issue": "No", 
                "time_frame": "Randomization (Day 0) and Day 42"
            }, 
            {
                "measure": "Change in pain assessment measured by the Visual Analog Scale", 
                "safety_issue": "No", 
                "time_frame": "Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56"
            }, 
            {
                "measure": "Change in pain assessment measured by Short-Form McGill Pain Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Randomization (Day 0) and Day 42"
            }, 
            {
                "description": "Pain reduction of ranolazine versus placebo in subjects with diabetic peripheral neuropathic pain (DPNP) and arterial ischemia compared to those with DPNP without arterial ischemia.", 
                "measure": "Change in pain of patients with arterial ischemia measured by Short-Form McGill Pain Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56"
            }, 
            {
                "description": "Additional pain medication after the baseline visit as needed for pain reduction in addition to the study drug.", 
                "measure": "Additional pain medication", 
                "safety_issue": "No", 
                "time_frame": "Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56"
            }, 
            {
                "description": "The rates and severity of Adverse Events (AEs) from Randomization (Day 0) through Termination (Day 56)", 
                "measure": "Occurrence of Adverse Events after randomization", 
                "safety_issue": "Yes", 
                "time_frame": "56 Days"
            }, 
            {
                "description": "A serious adverse event (SAE), also may be called a serious adverse drug reaction, is any untoward medical occurrence that at any dose:\nresults in death,\nis life-threatening,\nrequires inpatient hospitalization or prolongation of existing hospitalization,\nresults in persistent or significant disability/incapacity, or\nis a congenital anomaly/birth defect.", 
                "measure": "Occurrence of Serious Adverse Events after randomization", 
                "safety_issue": "Yes", 
                "time_frame": "56 Days"
            }
        ], 
        "source": "Horizons International Peripheral Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Horizons International Peripheral Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}